References:
- WHO Classification of Tumours Editorial Board. (2021). WHO classification of tumours: Thoracic tumours (5th ed.). International Agency for Research on Cancer.
- International Academy of Cytology, International Agency for Research on Cancer, & World Health Organization Joint Editorial Board. (2022). WHO reporting system for lung cytopathology (1st ed.). International Agency for Research on Cancer.
- Dermawan, Josephine Kam Tai, and Maria Luisa Policarpio-Nicolas. “Malignancies in Pleural, Peritoneal, and Pericardial Effusions.” Archives of pathology & laboratory medicine vol. 144,9 (2020): 1086-1091. doi:10.5858/arpa.2019-0429-OA
- Husain, Aliya Noor et al. “Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.” Archives of pathology & laboratory medicine vol. 142,1 (2018): 89-108. doi:10.5858/arpa.2017-0124-RA
- Michael, Claire W. “The cytologic diagnosis of mesothelioma: are we there yet?.” Journal of the American Society of Cytopathology vol. 12,2 (2023): 89-104. doi:10.1016/j.jasc.2022.12.001
- Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: Best current evidence from the literature and the International Mesothelioma Panel. (2020). Modern Pathology, 33(2), 281–296.
- Churg, A., Galateau-Salle, F., Roden, A. C., et al. (2020). Malignant mesothelioma in situ: Morphologic features and clinical outcome. Modern Pathology, 33(2), 297–302.
- Miettinen, M., McCue, P. A., Sarlomo-Rikala, M., et al. (2014). GATA3: A multispecific but potentially useful marker in surgical pathology. The American Journal of Surgical Pathology, 38(1), 13-22. https://doi.org/10.1097/PAS.0b013e3182a0218f
- Ordoñez, N. G., & Sahin, A. A. (2014). Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: A comparative study. Human Pathology, 45(7), 1529-1540. https://doi.org/10.1016/j.humpath.2014.03.006